Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer

Table 1 Baseline characteristics of 51 patients with primary liver cancer, n (%)

Item	Case
Gender
Male	42 (82.35)
Female	9 (17.65)
Age
< 60	7 (13.73)
≥ 60	44 (86.27)
Viral infection
No	11 (21.57)
HBV	34 (66.67)
HCV	4 (7.84)
HBV + HCV	2 (3.92)
Child-Pugh grade
A	45 (88.24)
B	6 (11.76)
BCLC
B	11 (21.57)
C	40 (78.43)
Tumor number
1	20 (39.22)
≥ 2	31 (60.78)
Tumor diameter
< 5 cm	19 (37.25)
≥ 5 cm	32 (62.75)

HBV: Hepatitis B virus; HCV: Hepatitis C virus; BCLC: Barcelona clinic liver cancer.

Table 2 Clinical efficacy evaluation of 51 patients with primary liver cancer, n (%)

Item	Case
CR	0 (0)
PR	27 (52.94)
SD	16 (31.37)
PD	8 (15.69)
Objective response rate	27 (52.94)
Disease control rate	43 (84.31)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 3 Changes in liver function indices before and after treatment (mean ± SD)

	Before (n = 51)	After (n = 51)	t	P value
ALT (U/L)	75.11 ± 4.62	60.62 ± 4.09	16.771	0
AST (U/L)	119.47 ± 11.69	41.57 ± 6.88	41.013	0
LDH (U/L)	439.15 ± 20.62	236.73 ± 18.15	52.623	0
AFP-13 (%)	18.52 ± 5.37	11.31 ± 2.65	8.598	0

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LDH: Lactate dehydrogenase; AFP-L3: Alpha-fetoprotein isoform.

Table 4 Incidence of adverse events, n (%)

	Incidence	Grade 3-5
Hypertension	10 (19.61)	4 (7.84)
Platelet reduction	14 (27.45)	2 (3.92)
ALT elevation	7 (13.73)	1 (1.96)
Leukocyte reduction	13 (25.49)	3 (5.88)
Nausea and vomiting	20 (39.22)	1 (1.96)
Fever	3 (5.88)	0 (0.00)
Hypothyroidism	2 (3.92)	0 (0.00)
Abdominal pain	4 (7.84)	0 (0.00)
Hyperbilirubinemia	6 (11.76)	0 (0.00)
Ascites	3 (5.88)	0 (0.00)
Hypokalemia	2 (3.92)	0 (0.00)